Garadacimab (Andembry)

Canada’s Drug Agency (CDA-AMC) recommends that Andembry be reimbursed by public drug plans for routine prevention of episodes (also known as attacks) of hereditary angioedema (HAE) in adult and pediatric patients (aged 12 years and older) if certain conditions are met. Andembry should only be covered for adult and pediatric patients (aged 12 years and older) with HAE according to the criteria used by public drug plans for long-term prophylaxis (LTP) currently reimbursed for the prevention of HAE episodes. In addition to following pre-existing criteria for long-term prophylactic treatments currently reimbursed for the prevention of HAE episodes, Andembry should not be used in combination with other medications for long-term prevention of angioedema. The cost of Andembry does not exceed the drug program cost of treatment with the least costly LTP for HAE.